J.B. Chemicals & Pharmaceuticals per share figures

Share price at each year-end
Tap a line for its trendFY26Mar 2026FY25Mar 2025FY24Mar 2024FY23Mar 2023FY22 and earlierAlpha Plus
₹45.16₹42.45₹35.66₹53.00
FY22 and earlierEvery year the company has filed comes with Alpha Plus.
₹44.45₹41.56₹34.85₹52.34
₹258.98₹220.51₹188.36₹320.46
₹258.27₹251.64₹224.50₹406.88
₹43.83₹57.96₹51.59₹80.83
₹43.83₹50.23₹34.75−₹18.00
₹19.51₹15.22₹10.12₹16.48
16.115.615.57.7
Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

JBCHEPHARM

J.B. Chemicals & Pharmaceuticals Ltd.

· Pharma & Health
₹ CrorePeersTORNTPHARMALKEMIPCALABSAILIFENHNEULANDLABACUTAASNATCOPHARM
HighlightsEnterprise ValueMultiplesPer ShareAnnuals · FY-end closes
₹ per share
12 Months Ending
FY23
31/03/2023
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Basic EPS53.0035.6642.4545.16
Diluted EPS52.3434.8541.5644.45
Book Value per Share320.46188.36220.51258.98
Revenue per Share406.88224.50251.64258.27
Cash Flow per Share80.8351.5957.9643.83
Free Cash Flow per Share-18.0034.7550.2343.83
Dividends per Share16.4810.1215.2219.51
Shares Outstanding (cr)7.715.515.616.1
Market Cap/EV/multiples pair each (split/bonus-adjusted) FY-end close with the latest filed share count; Current column uses the last close. Market Capitalization is a market-level figure — identical across Consolidated/Standalone (the accounting rows below differ). No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.